Claims
- 1. A compound that binds to IL-5 receptor, said compound comprising:
- (1) a core sequence of amino acids:
- CX.sub.1 X.sub.2 W X.sub.3 R C X.sub.4 X.sub.5 C
- where X.sub.1 is G, I, V, or Y; X.sub.2 is D or E; X.sub.3 is A or V; X.sub.4 is Q or P; and X.sub.5 is A, E, K, M, N, S, or T, (SEQ ID NO:1) and dimers and oligomers thereof, having
- (a) a molecular weight of less than about 5000 daltons, and
- (b) a binding affinity to IL5-R as expressed by an IC.sub.50 of no more than about 100 .mu.m,
- wherein from zero to all of the --C(O)NH-- linkages of the peptide have been replaced by a linkage selected from the group consisting of a --CH.sub.2 OC(O)NR-- linkage; a phosphonate linkage; a --CH.sub.2 S(O).sub.2 NR-- linkage; a --CH.sub.2 NR-- linkage; and a --C(O)NR.sup.6 -- linkage; and a --NHC(O)NH-- linkage where R is hydrogen or lower alkyl and R.sup.6 is lower alkyl,
- further wherein the N-terminus of said peptide or peptide mimetic is selected from the group consisting of a --NRR.sup.1 group; a --NRC(O)R group; a --NRC(O)OR group; a --NRS(O).sub.2 R group; a --NHC(O)NHR group; a succinimide group; a benzyloxycarbonyl-NH-- group; and a benzyloxycarbonyl-NH-- group having from 1 to 3 substituents on the phenyl ring selected from the group consisting of lower alkyl, lower alkoxy, chloro, and bromo, where R and R.sup.1 are independently selected from the group consisting of hydrogen and lower alkyl,
- and still further wherein the C-terminus of said peptide or peptide mimetic has the formula --C(O)R.sup.2 where R.sup.2 is selected from the group consisting of hydroxy, lower alkoxy, and --NR.sup.3 R.sup.4 where R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen and lower alkyl and where the nitrogen atom of the --NR.sup.3 R.sup.4 group can optionally be the amine group of the N-terminus of the peptide so as to form a cyclic peptide,
- or physiologically acceptable salts thereof.
- 2. The compound of claim 1, wherein said compound comprises a sequence of amino acids:
- C X.sub.1 X.sub.2 W X.sub.3 R C X.sub.4 X.sub.5 C
- where X.sub.1 is V; X.sub.2 is E; X.sub.3 is A; and X.sub.4 is P (SEQ ID NO:2).
- 3. The compound of claim 2, wherein said compound comprises either a sequence of amino acids:
- X.sub.6 X.sub.7 X.sub.8 V C X.sub.1 X.sub.2 W X.sub.3 R C X.sub.4 X.sub.5 C
- where X.sub.6 is D, E, G, I, M, N, P, Q, S, V, or Y; X.sub.7 is G, V, or Y; and X.sub.8 is F, W, or Y (SEQ ID NO:3); or a sequence of amino acids:
- C X.sub.1 X.sub.2 W X.sub.3 R C X.sub.4 X.sub.5 C X.sub.9
- where X.sub.9 is E, I, K, L, M, Q, R, T, V, or Y (SEQ ID NO:4).
- 4. The compound of claim 3, wherein said compound comprises a sequence of amino acids:
- X.sub.6 X.sub.7 X.sub.8 V C X.sub.1 X.sub.9 W X.sub.3 R C X.sub.4 X.sub.5 C X.sub.9
- (SEQ ID NO:65).
- 5. The compound of claim 4, wherein X.sub.6 is D, E, G, N, P, or Q; X.sub.7 is G; and X.sub.9 is K, L, Q, R, or T (SEQ ID NO:5).
- 6. The compound of claim 5, wherein X.sub.6 is D, N, or P; X.sub.8 is F or Y; and X.sub.9 is K, R, or T(SEQ ID NO:6).
- 7. The compound of claim 6, wherein said compound is selected from the group consisting of: D G Y V C V E W A R C P T C K (SEQ ID NO:7); D G Y V C V E W A R C P M C T (SEQ ID NO:8); and D G F V C V E W A R C P N C R (SEQ ID NO:9).
- 8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 9. An aerosol composition for the treatment of an inflammatory disorder of the respiratory tract that is mediated by IL-5 comprising a therapeutically effective amount of a compound of claim 1 in an aerosolized pharmaceutically acceptable carrier solution or dry powder.
- 10. The composition of claim 9 wherein said inflammatory disorder of the respiratory tract is asthma.
- 11. The composition of claim 9 wherein said compound of claim 1 is present in said carrier solution in a concentration of from 0.1 to 30 mg/mL.
- 12. The composition of claim 9 further comprising a .beta.-adrenergic agonist compound.
- 13. The composition of claim 9 wherein said .beta.-adrenergic agonist compound if selected from the group consisting of albuterol, terbutaline, formoterol, fenoterol, and prenaline.
- 14. The composition of claim 9 further comprising an antiinflammatory corticosteroid.
- 15. The composition of claim 14 wherein said antiinflammatory corticosteroid is selected from the group consisting of beclomethasome, triamcinolone, flurisolide, and dexamethasone.
- 16. The composition of claim 9 further comprising ipratropium bromide.
- 17. An aerosol device comprising:
- a composition of claim 9, and
- means for converting said solution or dry powder into an aerosol form suitable for inhalation.
CROSS-REFERENCE TO RELATED CASES
This application is related to the subject matter of U.S. patent application Ser. Nos. (Attorney Docket no. 1088.1A, 1088.1B, and 1088.2B), each of which is filed simultaneous herewith and is entitled "PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-5 RECEPTOR", and each of which is expressly incorporated herein by reference.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5096704 |
Coffman et al. |
Mar 1992 |
|
5143854 |
Pirrung et al. |
Sep 1992 |
|
5270170 |
Schatz et al. |
Dec 1993 |
|
5338665 |
Schatz et al. |
Aug 1994 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2058003 |
Jun 1992 |
CAX |